insights_auto
Why is DMN up 3,10%?
Dive Deeperchevron_right
DMN:FRA
Diamyd Medical AB
0,070 €
arrow_upward
+3,10%(+0,0021) 1D
11 նոյ, 15:48:50 GMT+1 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for DMN...
Open
0,07 €
High
0,07 €
Low
0,07 €
Mkt. cap
140,09 մլն
Avg. vol.
0,00
Volume
0,00
52-wk high
1,80 €
52-wk low
0,05 €
No. of employees
42
Open
0,07 €
High
0,07 €
Low
0,07 €
Mkt. cap
140,09 մլն
Avg. vol.
0,00
Volume
0,00
52-wk high
1,80 €
52-wk low
0,05 €
No. of employees
42
News stories
From web sources and news partners
Benzinga
·
14 րոպե առաջ
Nasdaq 100 Jumps 2.8% on CoreWeave, AI Rebound: Stock Market Today - Invesco QQQ Trust, Series 1 (NASDAQ
The Globe and Mail
·
34 րոպե առաջ
3 Unstoppable Nasdaq-100 Stocks to Buy in November
The Motley Fool
·
1 ժամ առաջ
Okta’s Real Opportunity Isn’t Its S&P 500 Spot. It’s AI Agents.
Reuters
·
7 ժամ առաջ
Mapping the Market: S&P 500 at risk of further losses
Profile
Diamyd Medical AB is a small biotechnology company headquartered in Stockholm, Sweden that focuses on immune modifying therapies for type-1 diabetes. The company's investigational drug retogatein is based on a recombinant form of GAD₆₅, one of two human glutamate decarboxylase gene products.
The company is headquartered in Stockholm, and maintains a "biomanufacturing" facility in Umeå which utilizes bacuolavirus-mediated protein expression. Wikipedia
About Diamyd Medical AB